Fig. 1 · Structure

Documents & Downloads

Phenytoin sodium

Cat. No. A10722 CAS 630-93-3
Phenytoin sodium (Dilantin) is a sodium channel protein inhibitor.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
Sodium channel

Phenytoin sodium Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Phenytoin sodium from 3 published references. In vitro models include left ventricular rabbit wedge preparations; HEK-293 cells stably transfected with hNaV1.5 cDNA. In vivo models include zebrafish (Danio rerio) stocks of the Ekkwill strain.

Phenytoin sodium In Vitro Studies

Phenytoin decreased QT interval duration in left ventricular rabbit wedge preparations compared with no drug. In HEK-293 cells stably transfected with hNaV1.5 cDNA, its INa IC50 was 49 000 nM. In hiPS-CMs (Cor 4U), Phenytoin produced negligible changes in CTD90 compared with no drug. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Phenytoin decreases QT interval in rabbit ventricular wedge preparations

Cell-based study · left ventricular rabbit wedge preparations [1]

In left ventricular rabbit wedge preparations, Phenytoin decreased QT interval duration compared with no drug.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
QT interval durationReported result a decrease in QT interval in rabbit wedge[1]

Literature-Reported Treatment Conditions

Reported limits
Not stated in the sentences used: dose, route, schedule, vehicle.
Methods and source locations

Compound reported in the paper: Phenytoin

The paper names Phenytoin without stating the salt or form; not verified as the sodium form supplied as A10722. No dose conversion or lot validation.

Materials and methods > Experimental drug assays (S47, S48); Results > In silico drug assays are in agreement with rabbit wedge and hiPs-CM experimental recordings (S122); Figure 5 legend (S155)

QT interval duration: QT interval duration; comparator: no drug — Materials and methods > Experimental drug assays (S48); Results > In silico drug assays are in agreement with rabbit wedge and hiPs-CM experimental recordings (S122)

Phenytoin inhibition of INa in transfected cells

Cell-based study · HEK-293 cells stably transfected with hNaV1.5 cDNA [2]

In HEK-293 cells stably transfected with hNaV1.5 cDNA, Phenytoin had an INa IC50 of 49 000 nM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
INa IC50 valuesNa IC50 49 000 nM[2]

Literature-Reported Treatment Conditions

Reported limits
Not stated in the sentences used: dose, route, schedule, vehicle, control.
Methods and source locations

Compound reported in the paper: Phenytoin

The paper names Phenytoin without stating the salt or form; not verified as the sodium form supplied as A10722. No dose conversion or lot validation.

Methods > IC50 and EFTPC values (S9, S12); Table 1 legend (S120); Table 1 (T1.h1, T1.r19)

INa IC50 values: INa IC50 values — Methods > IC50 and EFTPC values (S12); Table 1 legend (S120); Table 1 (T1.h1, T1.r19)

Phenytoin produces negligible changes in cardiomyocyte duration readout

Cell-based study · hiPS-CMs (Cor 4U) [1]

In hiPS-CMs (Cor 4U), Phenytoin produced negligible changes in CTD90 compared with no drug.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
duration at 90% of the initial base value (CTD90)Reported result negligible changes[1]

Literature-Reported Treatment Conditions

Reported limits
Not stated in the sentences used: dose, route, schedule, vehicle.
Methods and source locations

Compound reported in the paper: Phenytoin

The paper names Phenytoin without stating the salt or form; not verified as the sodium form supplied as A10722. No dose conversion or lot validation.

Materials and methods > Experimental drug assays (S49, S51); Results > In silico drug assays are in agreement with rabbit wedge and hiPs-CM experimental recordings (S122); Figure 5 legend (S155)

duration at 90% of the initial base value (CTD90): duration at 90% of the initial base value (CTD90); comparator: no drug — Materials and methods > Experimental drug assays (S51); Results > In silico drug assays are in agreement with rabbit wedge and hiPs-CM experimental recordings (S122)

Phenytoin sodium In Vivo Studies

Phenytoin was evaluated in Ekkwill-strain zebrafish with PTZ, using average larval locomotor activity and comparison with VHC+PTZ controls. The reported result was: “All other AEDs were not active at their MTCs.” [3]

Phenytoin evaluation in Ekkwill zebrafish

Animal study · Zebrafish (Danio rerio) stocks of the Ekkwill strain [3]

Phenytoin was evaluated in Ekkwill-strain zebrafish with PTZ, using average larval locomotor activity and comparison with VHC+PTZ controls. The reported result was: “All other AEDs were not active at their MTCs.”

Measured endpoints — not treatment concentrations
EndpointReported resultReference
average larval locomotor activity within 30 minutesReported result All other AEDs were not active at their MTCs[3]

Conditions shared by the study groups

Treatment course
30-min integration time
Vehicle
DMSO concentration of 1% w/v
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Phenytoin 100 µMVHC+PTZ controlsAll other AEDs were not active at their MTCs[3]
Phenytoin 100 µM
Model: Zebrafish (Danio rerio) stocks of the Ekkwill strain
Reported limits: Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Phenytoin

The paper names Phenytoin without stating the salt or form; not verified as the sodium form supplied as A10722. No dose conversion or lot validation.

Materials and Methods > Animals (S1); Materials and Methods > Drugs (S8); Results > Proconvulsant Treatment (S30); Results > Test of AEDs in the Larval Zebrafish PTZ Assay (S38, S39); Figure 3 legend (S58); Figure 4 legend (S66); Figure 5 legend (S69); Figure 6 legend (S71); Table 1 (T1.h1, T1.h2, T1.h3, T1.r8)

average larval locomotor activity within 30 minutes: average larval locomotor activity within 30 minutes; comparator: VHC+PTZ controls — Results > Test of AEDs in the Larval Zebrafish PTZ Assay (S39); Figure 3 legend (S58); Table 1 (T1.h1, T1.h3, T1.r8)

Phenytoin 100 µM · Results > Test of AEDs in the Larval Zebrafish PTZ Assay (S38, S39); Table 1 (T1.h1, T1.h2, T1.h3, T1.r8)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 630-93-3
Formula C15H11N2NaO2
Molecular Weight 274.25
Synonyms Aleviatin; Diphenylhydantoin sodium; Eptoin; Phenytoin soluble; Prompt; Phenytek; Dilantin
SMILES
C1=CC=C(C=C1)C2(C(=O)[N-]C(=O)N2)C3=CC=CC=C3.[Na+]

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 28 mg/mL (102.1 mM)
Water 3 mg/mL (10.93 mM)
Ethanol 10 mg/mL (36.45 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Phenytoin sodium Research References

  1. [1] Passini E, Britton OJ, Lu HR, et al. Human In Silico Drug Trials Demonstrate Higher Accuracy than Animal Models in Predicting Clinical Pro-Arrhythmic Cardiotoxicity. Front Physiol (2017). PMID: 28955244 DOI: 10.3389/fphys.2017.00668 Source material
  2. [2] Mirams GR, Cui Y, Sher A, et al. Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk. Cardiovasc Res (2011). PMID: 21300721 DOI: 10.1093/cvr/cvr044 Source material
  3. [3] Afrikanova T, Serruys AS, Buenafe OE, et al. Validation of the zebrafish pentylenetetrazol seizure model: locomotor versus electrographic responses to antiepileptic drugs. PLoS One (2013). PMID: 23342097 DOI: 10.1371/journal.pone.0054166 Source material

Added to your cart

View Cart Checkout
Loading...